Finally, the STK11-downstream targets, SIK1 and SIK3, mediate much of the anti-tumour effect of STK11, therefore therapies targeting chronic up-regulation of CREB-dependent transcription which drives IL-6 production could be explored36. This evidence concerns the gene SIK3 and neoplasm.